Reovirus and other oncolytic viruses for the targeted treatment of cancer

Selectivein vitrocytotoxic effect of human cancer cells by Bluetongue virus-10

“…The current mechanisms of oncolytic Reovirus towards human cancer cells have recently been summarized [18]. An activated Ras/RalGEF/p38 pathway is potentially involved with the permissiveness of host cells to Reovirus infection [20,21].…”

Reovirus therapy in cancer: has the orphan virus found a home?

“…This is followed by receptormediated endocytic uptake through interactions between capsid protein λ 2 and cellular β 1 integrins, outer shell uncoating and transmembrane penetration into the cytoplasm, where replication occurs [12] . Primary transcription occurs within the core or inner capsid through the activation of the viral RNA-dependent RNA polymerase, with the release of capped mRNAs.…”

“…Primary transcription occurs within the core or inner capsid through the activation of the viral RNA-dependent RNA polymerase, with the release of capped mRNAs. Primary transcripts and protein products then together form RNA, which undergoes secondary transcription and translation to generate new progeny for release [12,13] .…”

“…The outer shell proteins serve to introduce the inner capsid protein into the cytoplasm, with the σ 1 protein functioning as the viral attachment protein. dsRNA, double-stranded RNA.Adapted fromVidal et al 2006, with kind permission from Springer Science and Business Media[12] .…”

Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells

“…Antibody neutralization and hemagglutination-inhibition studies have identified three distinct serotypes of reovirus [Type 1 Lang, Type 2 Jones, Type 3 Abney, and Type 3 Dearing (T3D)] (1, 3, 5). …”